U.S. Court in New Jersey Says Janssen Must Pay $1.64 Billion for Off-Label Drug Marketing Fraud
- April 04, 2025
A federal court in New Jersey ordered Janssen Products, LP to pay nearly $1.64 billion after a jury found its marketing practices for two HIV drugs resulted in the submission of false claims for reimbursement to federal health care programs.
ARTICLE TAGS
You must be logged in to access this content.